Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Fallopian Tube Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(88)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
FOLR1 positive
Fallopian Tube Cancer
FOLR1 positive
Fallopian Tube Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
MSI-H/dMMR
Fallopian Tube Cancer
MSI-H/dMMR
Fallopian Tube Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
NTRK3 fusion
Fallopian Tube Cancer
NTRK3 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Fallopian Tube Cancer
NTRK2 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Fallopian Tube Cancer
NTRK1 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login